Coronavirus Update: Japan Approves Sotrovimab
Plus, Indian Trial For Novavax/Serum Vaccine
Japan approves a second antibody therapy for COVID-19 in short order, while India gives the go-ahead to a local clinical program for Novavax/Serum Institute's recombinant protein vaccine candidate.
You may also be interested in...
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.
While delays to manufacturing have frustrated the vaccine’s submission, Novavax is still confident its nanoparticle-based jab will play a significant role in COVID-19.
With an emergency approval, Zydus Cadila has commercialized the world’s first plasmid DNA vaccine for human use and the first COVID-19 vaccine for use in adolescents in India. Will efficacy against the Delta variant help tide over hesitancy towards a new technology or a lack of publicly published data hamper acceptance?